Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up. Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting. Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting. FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis. Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment. Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing. Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma. Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM. DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation Researchers said there was a need for potentially more effective one-time-only treatment options. Narazaciclib plus ibrutinib regulated signatures associated with DNA repair, P53 signaling, and glycolytic activity. Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma. Dr. Brown presented updated results from the ALPINE study at ASH 2023. ELEVATE-TN enrolled 535 patients, of which 179 received acalabrutinib. The study included 16 baseline and 18 post-infusion tumor samples from 26 patients. The trial established the recommended phase II dose of acalabrutinib, venetoclax, and obinutuzumab. The median overall survival was 44.9 months with ibrutinib plus venetoclax versus 38.6 months with ibrutinib plus placebo. The study compared characteristics, step up dosing process, and incidence and management of cytokine release syndrome. Dr. Woyach joined Chadi Nabhan, MD, MBA, FACP, to discuss the novel BTK inhibitors pirtobrutinib and LP168. It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy.